Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Apr 08, 2026
Why Is Exxon Mobil (XOM) Stock Down -5.6% Today?

Why Is Exxon Mobil (XOM) Stock Down -5.6% Today?

Key Takeaways

  • XOM is trading down approximately 5.62% in Wednesday premarket, with shares sliding to around $154.70 from Tuesday's closing price of $163.91
  • The primary catalyst is the surprise US-Iran two-week ceasefire announced on Tuesday evening, April 7, just before President Trump's 8 PM ET deadline
  • As part of the deal, Iran agreed to reopen the Strait of Hormuz — the world's most critical oil chokepoint — sending crude prices into freefall
  • West Texas Intermediate crude tumbled as much as 19%, its largest single-day drop since 2020, falling below $100 a barrel
  • The broader energy sector is under heavy pressure, with peers Chevron (CVX) and Occidental Petroleum (OXY) also sharply lower in premarket
  • Traders are watching whether the ceasefire holds and whether two weeks of negotiations produce a durable long-term agreement

Opening Summary

Exxon Mobil Corporation (XOM) is one of the world's largest publicly traded oil and gas companies, engaged in the exploration, production, refining, and sale of petroleum and petrochemical products across the globe. In Wednesday's premarket session, XOM shares are indicated at approximately $154.70, a decline of $9.21 (-5.62%) from Tuesday's official close of $163.91. The move directly tracks a dramatic collapse in crude oil prices triggered by an unexpected US-Iran ceasefire agreement announced on the evening of April 7, 2026.

The Iran Ceasefire: The Core Catalyst

Less than two hours before President Trump's threatened 8 PM ET deadline — which he had warned would result in catastrophic military escalation — the United States and Iran agreed to a two-week ceasefire, brokered by Pakistan.  As part of the deal, Iran committed to the "complete, immediate, and safe opening" of the Strait of Hormuz, the narrow waterway through which approximately 20% of the world's oil and gas supply flows.  The strait had effectively been closed since the conflict began in late February, creating the most significant oil supply disruption in modern history, impacting an estimated 12–15 million barrels of oil per day.

Trump announced on Truth Social that the ceasefire represents a "double-sided" pause on hostilities, with the US and Israel suspending bombing operations and Iran halting its military operations in kind.  He noted that Iran had submitted a 10-point peace proposal, which he described as a "viable foundation for negotiations," and that the two weeks are intended to finalize a longer-term peace agreement.

Oil Price Collapse Hammers Energy Stocks

The ceasefire announcement triggered an immediate and violent selloff in crude oil markets. West Texas Intermediate crude tumbled nearly 19% — its sharpest intraday drop since 2020 — falling toward the $91 per barrel range, before settling around $96.48 as markets digested the news.  Brent crude, the international benchmark, similarly collapsed, shedding approximately $13–14 per barrel to land near $95.48.  Natural gas futures also declined around 5%, compounding the pressure across the entire energy complex.

For XOM, whose revenues and earnings are directly tied to realized crude and natural gas prices, a rapid drop of this magnitude in commodity prices immediately reprices near-term earnings expectations downward. The stock had rallied significantly since late February as the conflict drove oil prices sharply higher, with shares climbing from below $150 to a 52-week high of $176.41.  Wednesday's premarket retreat partially unwinds that war premium.

Sector-Wide Energy Selloff

The selloff is not isolated to XOM — the entire energy sector is under broad pressure as traders reprice the oil market outlook. Chevron (CVX) dropped approximately 4.6–5.1% in premarket, while other major energy names followed suit.  Meanwhile, in a notable divergence, the broader equity market is staging a relief rally: airline stocks, cruise lines, and consumer discretionary names are surging on lower fuel cost expectations, while tech and defense stocks are also gaining as geopolitical risk premiums deflate.  This sector rotation — selling energy, buying the rest — reinforces the directional signal for XOM.

Market Context and Trading Activity

Premarket volume in XOM is elevated relative to its 30-day average premarket volume, reflecting the urgency of repositioning following the overnight geopolitical shock.  On the technical side, the drop brings XOM back toward the $154–$155 range, a level that previously acted as support in early March 2026 and could be a near-term area of attention for traders.  The broader energy sector ETFs, including XLE, are expected to open sharply lower in sympathy. Importantly, while global equity indices including Asian benchmarks jumped on ceasefire relief, energy stocks are the clear exception — a divergence that highlights just how much of the sector's recent gains were built on the war premium in oil.

Trending AI Robots

For investors navigating the rapid shifts in energy and broader market conditions, Tickeron's Trending AI Robots page offers a curated view of the platform's top-performing AI trading bots under current market conditions. Tickeron operates hundreds of AI-powered bots covering thousands of tickers across sectors, timeframes, and strategies — but only the strongest performers, ranked by recent metrics, appear in the Trending section. Bots vary by trading style, holding period, risk profile, and the symbols they trade, giving investors a range of approaches to choose from. Whether you're looking for momentum-based strategies, mean-reversion models, or sector-specific tools, exploring the Trending AI Robots page can surface actionable ideas aligned with today's fast-moving environment.

What Comes Next for XOM

The most immediate question for XOM investors is whether the two-week ceasefire translates into a durable peace agreement — or unravels, sending oil prices back higher. Analysts caution that the 10-point framework Iran has proposed contains significant sticking points, including demands for the recognition of Iran's nuclear enrichment program and the lifting of all US sanctions, making a permanent deal far from certain.  On the fundamental calendar, Exxon Mobil is expected to report its Q1 2026 earnings in late April or early May, and those results will reflect a quarter during which oil prices were elevated due to the conflict — offering near-term earnings support even as the forward outlook clouds. Longer term, investors will be watching oil price stabilization levels, the durability of the Strait of Hormuz reopening, and any analyst revisions to price targets that had been set under wartime commodity conditions. Risks to the downside include a faster-than-expected decline in crude toward pre-war levels, while a ceasefire breakdown would likely reignite the war premium that lifted the stock throughout February and March.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitation

Related Ticker: XOM

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


Momentum Indicator for XOM turns positive, indicating new upward trend

XOM saw its Momentum Indicator move above the 0 level on October 01, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 91 similar instances where the indicator turned positive. In 58 of the 91 cases, the stock moved higher in the following days. The odds of a move higher are at 64%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a +0.77% 3-day Advance, the price is estimated to grow further. Considering data from situations where XOM advanced for three days, in 231 of 373 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

The Moving Average Convergence Divergence Histogram (MACD) for XOM turned negative on September 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 27 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 54%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XOM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 43%.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 6 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 28, placing this stock better than average.

The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. XOM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 62 (best 1 - 100 worst), indicating slightly weaker than average sales and a marginally profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: XOM's P/B Ratio (2.577) is slightly higher than the industry average of (1.887). P/E Ratio (20.916) is within average values for comparable stocks, (16.521). Projected Growth (PEG Ratio) (1.392) is also within normal values, averaging (1.088). Dividend Yield (0.025) settles around the average of (0.035) among similar stocks. P/S Ratio (1.911) is also within normal values, averaging (3.764).

Notable companies

The most notable companies in this group are ExxonMobil Holdings Corporation (NYSE:XOM), Chevron Corp (NYSE:CVX), Petroleo Brasileiro Sa-Petrobras ADS (REP 1 Common Share) (NYSE:PBR), BP plc (NYSE:BP), Suncor Energy (NYSE:SU), YPF Sociedad Anonima (NYSE:YPF).

Industry description

Integrated oil companies are involved across nearly the entire oil value chain – from upstream operations like exploration and production, to downstream functions of refining and marketing. Exxon Mobil Corporation, Chevron Corporation and BP are major integrated oil companies. Their bottom lines’ response to crude oil prices could depend on the proportion of upstream vs. downstream businesses; for example, if a company has substantial downstream business, the adverse impact on their upstream business due to falling crude prices could be mitigated by benefits to its downstream business.

Market Cap

The average market capitalization across the Integrated Oil Industry is 124.33B. The market cap for tickers in the group ranges from 63.2K to 668.27B. XOM holds the highest valuation in this group at 668.27B. The lowest valued company is CRRDF at 63.2K.

High and low price notable news

The average weekly price growth across all stocks in the Integrated Oil Industry was 3%. For the same Industry, the average monthly price growth was -0%, and the average quarterly price growth was 5%. PBR experienced the highest price growth at 17%, while TTE experienced the biggest fall at -5%.

Volume

The average weekly volume growth across all stocks in the Integrated Oil Industry was 61%. For the same stocks of the Industry, the average monthly volume growth was 65% and the average quarterly volume growth was -26%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 40
P/E Growth Rating: 50
Price Growth Rating: 47
SMR Rating: 55
Profit Risk Rating: 27
Seasonality Score: 14 (-100 ... +100)
View a ticker or compare two or three
XOM
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a distributer of crude oil, natural gas and petroleum products

Industry IntegratedOil

Industry
Integrated Oil
Address
22777 Springwoods Village Parkway
Phone
+1 972 940-6000
Employees
57900
Web
https://www.corporate.exxonmobil.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.
Rio Tinto holds a premier position as one of the world's largest mining companies, anchored by low-cost, Tier 1 assets. Its Pilbara iron ore operations in Australia deliver industry-leading margins, thanks to integrated rail and port infrastructure that gives it a structural cost advantage over higher-cost producers. In copper, the company has significant stakes in Escondida, the world's largest copper mine, and full ownership of Oyu Tolgoi in Mongolia, setting it up well to benefit from tightening supply as demand surges for electrification and renewables.
I've always been impressed by how Visa (V) commands the global payments landscape. As an open-loop network, it connects issuers, acquirers, merchants, and consumers without issuing cards or extending credit itself. The VisaNet platform processes over 65,000 transactions per second across more than 200 countries, supporting a ~52% share of the global credit card market and ~60% of debit. This scale generates powerful network effects, where greater adoption benefits everyone involved and creates formidable barriers to entry.
Following the Kenvue consumer health spin-off, Johnson & Johnson has transformed into a focused healthcare leader, emphasizing Innovative Medicine (pharmaceuticals) and MedTech (devices). In my view, this repositioning sharpens the company's edge in high-margin areas such as oncology, immunology, neuroscience, cardiovascular, surgery, and vision, where its diversified portfolio and R&D efficiency provide clear competitive advantages.
I've long appreciated ASML Holding N.V.'s dominant position in the semiconductor lithography market. The company commands over 90% share in advanced deep ultraviolet (DUV) immersion systems and 100% in EUV lithography—the critical technology for chips below 7nm nodes used in AI, high-performance computing, and memory. This near-monopoly comes from decades of R&D investment, exclusive partnerships like Zeiss for optics, and a vast installed base that generates steady service revenue. From what I see, competitors such as Nikon and Canon remain far behind in EUV, sticking to mature nodes.
I've been watching Micron Technology (MU) closely through its recent volatility, which mirrors the semiconductor sector's heightened sensitivity to AI demand and supply constraints. The stock saw a sharp post-earnings sell-off tied to elevated capital expenditure plans, yet it has rebounded with surging DRAM prices—up 90-95%—and memory suppliers booked out for years. From what I see, broader tech optimism, including key partnerships and persistent supply tightness, is driving upward momentum. This positions MU as a pivotal player in high-bandwidth memory (HBM) for data centers. Trading near recent highs around $368, the shares highlight investor focus on Micron's critical role in the AI infrastructure expansion under these constrained industry conditions.